Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Extended follow-up sits at the center of this dementia and brain health question.
Extended follow-up studies spanning three to four years confirm that Alzheimer’s disease medications, particularly monoclonal antibodies like lecanemab and donanemab, maintain a consistent and manageable safety profile over the long term. Recent data presented at major conferences in 2025, including the Alzheimer’s Association International Conference and the Clinical Trials on Alzheimer’s Disease summit, demonstrate that the safety concerns identified during initial trials do not worsen or expand as patients continue treatment. Lecanemab, marketed as Leqembi, showed no new safety findings after four years of continuous use in the Clarity AD open-label extension study, with amyloid-related imaging abnormalities (ARIA) rates actually decreasing after the critical first 12 months.
These findings address one of the primary hesitations caregivers and patients have about disease-modifying therapies: whether long-term exposure to these potent medications introduces unexpected risks. A 36-month safety analysis of lecanemab demonstrated that most ARIA cases occur within the first six months of treatment, after which the incidence stabilizes at rates similar to placebo. This pattern holds consistent across different patient populations and treatment protocols, providing evidence that physicians and families can have confidence in these therapies’ safety trajectories when properly monitored.
Table of Contents
- What Do Four-Year Safety Studies Reveal About Lecanemab Outcomes?
- Understanding ARIA Rates in Extended Treatment Periods
- Real-World Safety Data Validates Clinical Trial Results
- How Long-Term Benefits Sustain in Patients on Monoclonal Antibodies
- Managing Safety Monitoring Through Extended Therapy
- Emerging Data on Next-Generation Alzheimer’s Treatments
- Future Outlook for Long-Term Treatment Safety
- Conclusion
What Do Four-Year Safety Studies Reveal About Lecanemab Outcomes?
The Clarity AD open-label extension study represents one of the most comprehensive long-term investigations of lecanemab safety, following patients who initially enrolled in the pivotal Phase 3 trial. When results were presented at the Alzheimer’s Association international Conference in July 2025, the data showed a reassuring pattern: no new adverse events emerged during years two through four of continuous treatment, and the rates of both amyloid-related imaging abnormalities types (ARIA-E for microhemorrhages and ARIA-H for microinfarcts) decreased from their peak in the first year and remained consistent throughout the extended observation period. This means that patients who tolerated the initial 12 months without developing these imaging changes showed increasingly stable safety profiles in subsequent years.
The clinical significance of this finding cannot be overstated. In traditional drug trials, researchers often see a different safety profile emerge after several years of exposure, either because vulnerable patients drop out early or because long-term exposure reveals delayed effects. The fact that lecanemab does not follow this pattern suggests the medication’s risk-benefit profile becomes increasingly favorable over time as ARIA rates decline. Patients in their second and third years of therapy experienced fewer imaging abnormalities while continuing to accrue cognitive benefits, making continuation of therapy a more straightforward clinical decision.
Understanding ARIA Rates in Extended Treatment Periods
Amyloid-related imaging abnormalities represent the primary safety concern with anti-amyloid monoclonal antibodies, as these imaging findings can sometimes correlate with cognitive or neurological symptoms. The critical insight from extended follow-up studies is that ARIA occurrence follows a front-loaded pattern: the highest risk period is the first 18 months of treatment, with the vast majority of cases appearing in the initial six months. A three-year safety analysis examining lecanemab found that most ARIA cases occurred within this early window, and patients who remained ARIA-free at six months had a significantly lower likelihood of developing these imaging findings in subsequent years. However, a limitation worth noting is that not all imaging abnormalities produce noticeable symptoms.
Some patients show ARIA on MRI scans without experiencing headaches, confusion, or other clinical effects. The FDA, recognizing both the safety benefits of these medications and the need for proactive monitoring, recommended that physicians conduct additional and earlier MRI scans for patients taking Leqembi to catch ARIA cases promptly, even subclinical ones. This guidance reflects an important tradeoff: these medications offer meaningful cognitive benefits, but they require more intensive monitoring protocols than traditional dementia treatments. Caregivers should expect more frequent brain imaging during the first year and periodic scans thereafter.
Real-World Safety Data Validates Clinical Trial Results
While clinical trials provide controlled conditions for evaluating drug safety, real-world evidence shows how medications perform in actual clinical practice across diverse patient populations. ALZ-NET’s first real-world data readout, presented at the Clinical Trials on Alzheimer’s Disease conference in 2025, compared treatment patterns and patient demographics between clinical trial enrollees and community-based patients receiving the same therapies. The consistency was striking: early findings indicated stable cognition and function during the first year of therapy with ARIA rates matching clinical trial expectations. This alignment between controlled research and actual practice suggests that the safety profile observed in trials translates reliably to everyday clinical settings.
The real-world data becomes particularly important because clinical trial populations are often healthier and more homogeneous than the broader patient population. Trials typically exclude patients with multiple comorbidities, those taking certain medications, or those with advanced medical complexity. When patients with more complex medical histories receive lecanemab or donanemab in community settings, the maintained safety alignment indicates these medications work safely across a broader spectrum of individuals than formal trials usually demonstrate. However, this real-world monitoring remains preliminary, and longer follow-up from these community populations will further establish whether safety outcomes continue to align with trial expectations.
How Long-Term Benefits Sustain in Patients on Monoclonal Antibodies
While safety represents one pillar of long-term therapy success, sustained cognitive benefit represents another. The TRAILBLAZER-ALZ 2 long-term extension study evaluated donanemab, a newer anti-amyloid monoclonal antibody that requires less frequent infusions than lecanemab. This study demonstrated that donanemab provided meaningful cognitive benefit extending out to three years with no new safety concerns emerging.
More than 75% of participants in this trial achieved amyloid clearance within 76 weeks, indicating profound removal of the pathological protein burden associated with Alzheimer’s disease progression. An important nuance in donanemab’s profile is that amyloid slowly re-accumulates after initial clearance, at a rate of approximately 2.5 centiloids per year—a metric used to quantify amyloid burden on positron emission tomography imaging. This re-accumulation raises practical questions about long-term dosing strategies: will patients need boosters after their initial treatment course, or does the initial amyloid clearance provide durable benefit even as some amyloid gradually returns? These questions remain under investigation, but the three-year extension data suggests that cognitive stability persists even as modest amyloid re-accumulation occurs, providing hope that episodic treatment approaches might become viable future strategies.
Managing Safety Monitoring Through Extended Therapy
The FDA’s guidance on additional and earlier MRI monitoring reflects a fundamental principle in long-term anti-amyloid therapy: robust safety surveillance becomes part of the treatment protocol itself. Patients initiating lecanemab should anticipate baseline MRI imaging before treatment begins, repeat imaging at one to three months into therapy (during the period of highest ARIA risk), and then periodic surveillance MRIs, typically annually or as clinical symptoms warrant. This represents a significant commitment in terms of time, cost, and accessibility—MRI machines are not universally available in all communities, and the repeated procedures add to overall treatment burden. The tradeoff becomes particularly relevant for elderly patients with limited mobility or claustrophobia, both common concerns in the dementia population.
Some patients may decline anti-amyloid therapy not because of the medication itself but because the intensive MRI monitoring feels burdensome. Healthcare systems must balance disease-modifying benefits against monitoring logistical demands. Additionally, for patients with implanted medical devices incompatible with MRI—certain pacemakers or metallic implants—alternative imaging strategies or alternative medications must be considered. The extended follow-up studies confirm these safety protocols work, but they cannot eliminate the practical complexities inherent in monitoring that protocols require.
Emerging Data on Next-Generation Alzheimer’s Treatments
Beyond lecanemab and donanemab, Alzheon’s ALZ-801 represents another anti-amyloid approach currently under investigation, with an important distinction: this medication demonstrated an ARIA-free safety profile in Phase 3 data announced in April 2025, particularly in the mild cognitive impairment subgroup. An ARIA-free profile—meaning no microhemorrhages or microinfarcts on imaging—would represent a significant advance if sustained in broader patient populations, potentially simplifying safety monitoring requirements and reducing barriers to treatment adoption. The mechanism differs from other monoclonal antibodies, which may explain the divergent safety outcomes, though longer-term data must confirm whether ARIA-free profiles remain consistent through extended therapy.
This emerging data landscape illustrates an important principle: anti-amyloid therapies are not a monolithic category but rather a diverse group of medications with distinct safety and efficacy profiles. Future patients may benefit from pharmacological options tailored to their individual risk factors, comorbidities, and monitoring capacity. The extended follow-up studies of established medications like lecanemab and donanemab establish benchmarks against which newer agents can be compared, supporting increasingly precise treatment selection.
Future Outlook for Long-Term Treatment Safety
As anti-amyloid therapies transition from novel breakthrough treatments to established disease-modifying agents, the safety conversations evolve from “Are these medications safe?” toward “How do we optimize safety and access for diverse patient populations?” The four-year Clarity AD extension data and three-year TRAILBLAZER-ALZ 2 results provide crucial confidence that extended treatment does not reveal delayed or cumulative toxicities. Future research priorities include understanding optimal dosing schedules, identifying biomarkers that predict ARIA risk in individual patients, and developing streamlined monitoring protocols that preserve safety while reducing burden. The integration of real-world safety data into medical practice represents a particular frontier.
As more diverse patient populations access these medications outside tightly controlled clinical trials, maintaining robust safety registries and adverse event reporting becomes essential. The consistency observed thus far between trial and real-world ARIA rates is encouraging, but continued surveillance ensures that any divergent safety signals receive prompt detection and investigation. Extended follow-up studies ultimately enable not just confirmation of safety but refinement of how these life-altering therapies integrate into the broader dementia care continuum.
Conclusion
Extended follow-up studies spanning three to four years demonstrate conclusively that disease-modifying anti-amyloid monoclonal antibodies maintain consistent, manageable safety profiles throughout long-term treatment. The pattern of ARIA occurrence concentrating in the first six months, with declining rates thereafter, provides a predictable safety trajectory that enables informed decision-making by patients and caregivers. Lecanemab’s four-year safety data from Clarity AD, donanemab’s three-year benefit confirmation, and emerging real-world evidence all point toward these medications as sustainably safe therapies when deployed with appropriate monitoring protocols.
For individuals and families facing Alzheimer’s disease, these extended follow-up results translate into an increasingly clear message: if you tolerate the initial treatment period, the long-term safety outlook improves considerably. The commitment to intensive MRI monitoring and regular clinical assessment remains necessary, but that monitoring protects against a manageable risk profile rather than unknown dangers. As extended follow-up studies continue accumulating data through year five and beyond, confidence in these therapies’ long-term safety will only deepen, supporting their role as foundational treatments in slowing cognitive decline during the earliest stages of Alzheimer’s disease.
You Might Also Like
- Multi-Site Care Programs Improve Alzheimer’s Patient Experience
- Why Investing in Caregiver Health Is Actually Investing in Patient Health According to 5 Major Studies
- Why Public Investment in Education Today Is Actually an Investment in Dementia Prevention 50 Years From Now
For more, see CDC — Alzheimer’s and Dementia.
